WFI manufacturing and other capabilities support for pharmaceutical innovation, GLP‑1 therapies, and medical devices. ILC Dover, an Ingersoll Rand bus...
Ginkgo Bioworks announced that its Datapoints offering is launching ADME-One™, a fully integrated ADME platform for drug discovery teams co-de...
Award funds collaboration with leading Parkinson’s researcher, Dr. Tim Greenamyre, to investigate a novel therapeutic approach for Parkinson&rsqu...
Abivax Presents First Quarter 2026 Financial Results and Reports Three-Year Interim Data from Study 108, a Phase 2a/2b Open-Label Extension Trial of Obef...
In TRIUMPH-1, participants on 12 mg retatrutide lost an average of 70.3 lbs (28.3%) over 80 weeks with 45.3% of participants achieving ≥30% weig...
HDT Bio, a clinical-stage biotechnology company based in Seattle, Washington,announced that it received the Medical CBRN Defense Consortium (MCDC) Innova...
What's Coming to ASCO 2026: Sneak Peek at Transformative Cancer Research The American Society of Clinical Oncology (ASCO) 2026 Annual Meet...
Assembly Biosciences, Inc. (Nasdaq: ASMB), a biotechnology company developing innovative therapeutics targeting serious viral diseases, today announced p...
European Medicines Agency (EMA) has adopted a positive opinion recommending approval of nerandomilast for the treatment of idiopathic pulmonary fibrosis ...
United Immunity, Co., Ltd., a biotechnology company developing its proprietary Myeloid Targeting Platform™ for therapeutic in vivo engineerin...
New Biacore 8S and Biacore 8S+ systems combine rapid screening and high-quality molecular characterization in a single system Biacore Insight So...
ProtaGene announced a strategic partnership with the Life Science business of Merck, which operates as MilliporeSigma in the United States and Canada, to...
Global pharmaceutical leader Lupin Limited (Lupin) (BSE: 500257) (NSE: LUPIN) (REUTERS: LUPIN.BO) (BLOOMBERG: LPCIN) announced that it has received...
ATS: phase 2 data demonstrate the superiority of efdoralprin alfa over a standard-of-care augmentation therapy in achieving higher fAAT levels in AATD ...
© 2026 Biopharma Boardroom. All Rights Reserved.
